philip j. barter, et al. circulation 2011;124:555-562

8
Philip J. Barter, et al. Circulation 2011;124:555-562

Upload: mort

Post on 04-Jan-2016

36 views

Category:

Documents


0 download

DESCRIPTION

Philip J. Barter, et al. Circulation 2011;124:555-562. Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part I. Philip J. Barter, et al. Circulation 2011;124:555-562. Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part II. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Philip J. Barter, et al. Circulation 2011;124:555-562

Philip J. Barter, et al. Circulation 2011;124:555-562

Page 2: Philip J. Barter, et al. Circulation 2011;124:555-562

Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part I

Philip J. Barter, et al. Circulation 2011;124:555-562

Page 3: Philip J. Barter, et al. Circulation 2011;124:555-562

Baseline Characteristics of Randomized Subjects With Diabetes Mellitus – Part II

Philip J. Barter, et al. Circulation 2011;124:555-562

Page 4: Philip J. Barter, et al. Circulation 2011;124:555-562

Effects of Treatment With Atorvastatin vs the Combination of Atorvastatin and Torcetrapib on Plasma Glucose, Hemoglobin A1c, Serum Insulin,

HOMA-IR, and HDL Cholesterol for the Subgroup of Diabetic Subjects

Philip J. Barter, et al. Circulation 2011;124:555-562

Page 5: Philip J. Barter, et al. Circulation 2011;124:555-562

Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A1c, and HOMA-IR Adjusted for Change in HDL Cholesterol - I

Philip J. Barter, et al. Circulation 2011;124:555-562

Page 6: Philip J. Barter, et al. Circulation 2011;124:555-562

Philip J. Barter, et al. Circulation 2011;124:555-562

Between-Treatment Comparison of Changes in Glucose, Insulin, Hemoglobin A1c, and HOMA-IR Adjusted for Change in HDL Cholesterol - II

Page 7: Philip J. Barter, et al. Circulation 2011;124:555-562

Effects of Treatment With Atorvastatin vs the Combination of Atorvastatin and Torcetrapib on Plasma Glucose, Hemoglobin A1c, Serum Insulin,

HOMA-IR, and HDL Cholesterol for the Subgroup of Nondiabetic Subjects

Philip J. Barter, et al. Circulation 2011;124:555-562

Page 8: Philip J. Barter, et al. Circulation 2011;124:555-562

CLINICAL PERSPECTIVE

Philip J. Barter, et al. Circulation 2011;124:555-562